Vectus Biosystems Ltd (ASX: VBS) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Vectus Biosystems Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $6.92 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 53.21 million
Earnings per share -0.044
Dividend per share N/A
Year To Date Return -56.67%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Vectus Biosystems Ltd (ASX: VBS)
    Latest News

    Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
    Healthcare Shares

    Why is this ASX biotech share leaping 14% today?

    Human trial success is boosting this ASX biotech share today.

    Read more »

    VBS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Vectus Biosystems Ltd

    Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

    VBS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 May 2024 $0.13 $0.00 0.00% 10,000 $0.13 $0.13 $0.13
    27 May 2024 $0.13 $0.00 0.00% 7,079 $0.13 $0.13 $0.13
    24 May 2024 $0.13 $0.00 0.00% 10,000 $0.13 $0.13 $0.13
    23 May 2024 $0.13 $-0.01 -7.41% 559,670 $0.13 $0.15 $0.12
    22 May 2024 $0.14 $0.01 8.00% 519,656 $0.13 $0.16 $0.13
    21 May 2024 $0.13 $-0.04 -25.00% 310,265 $0.16 $0.16 $0.13
    20 May 2024 $0.16 $-0.04 -20.00% 212,491 $0.13 $0.16 $0.12
    16 May 2024 $0.20 $-0.04 -17.02% 50 $0.20 $0.20 $0.20
    02 May 2024 $0.24 $-0.02 -8.00% 5,360 $0.24 $0.24 $0.24

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Dec 2023 Karen Duggan Issued 19,842 $6,250
    As advised by the company. Bonus

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Maurie Stang Non-Executive Deputy ChairmanNon-Executive Director Dec 2005
    Mr Stang has more than three decades of experience building and managing companies in the healthcare and biotechnology industry in Australia and internationally. His strong business development and marketing skills have
    resulted in the successful commercialisation of intellectual property across global markets.
    Dr Ronald Cecil Shnier Non-Executive DirectorNon-Executive Chairman Sep 2015
    Dr Shnier completed his radiology fellowship at Royal Prince Alfred Hospital (RPAH) before undertaking his neuroradiology fellowship at RPAH in 1989 and musculoskeletal fellowship at the University of California Los Angeles. He was a consultant specialist at RPAH. Dr Shnier started one of Australia's first Private MRI practices before becoming General Manager of Mayne's Diagnostic Imaging and was its National Director for many years. He has served on several international MRI advisory boards. Dr Shnier has a strong involvement in clinical research and has lectured both in Australia and overseas. He is currently the Chief Medical
    Officer of I-MED Radiology network.
    Dr Susan Margaret Pond Non-Executive Director May 2016
    Dr Susan Pond has a scientific and commercial background, having held executive positions in the biotechnology and pharmaceutical industry for 12 years, including as Chairman and Managing Director of Johnson & Johnson Research Pty Limited. Dr Pond has held many Board positions such as: Non-Executive Director and Chairman of AusBiotech Limited; Director of the Australian Nuclear Science and Technology Organisation; Board member of Innovation Australia; and Vice President of the
    Academy of Technological Sciences and Engineering. She is a Fellow of ATSE, the Australian Institute of Company Directors, and the Academy of Health and Medical Sciences.
    Mr Robert John Waring Company Secretary
    Robert John Waring Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Kefford Holdings Pty Ltd <The Kefford Family A/C> 4,770,000 8.97%
    HSBC Custody Nominees (Australia) Limited 3,341,648 6.28%
    Ajjika Technology Pty Limited <The Ajjika A/C> 3,200,000 6.02%
    Bernard Stang 2,676,500 5.03%
    Energy Trading Systems Pty Ltd <The Mpf A/C> 2,562,500 4.82%
    Maurie Stang 2,285,952 4.30%
    Gleneagle Securities Nominees Pty Limited 1,611,596 3.03%
    Bennelong Resources Pty Ltd <John Egan Super Fund A/C> 1,500,000 2.82%
    Spinite Pty Ltd 1,435,773 2.70%
    Grizzly Holdings Pty Limited 1,407,035 2.65%
    Citicorp Nominees Pty Limited 1,362,470 2.56%
    Truebell Capital Pty Ltd <Truebell Investment Fund> 1,269,526 2.39%
    Esklaw Pty Ltd <Tom Forrester Family A/C> 1,000,000 1.88%
    Buttonwood Nominees Pty Ltd 795,190 1.50%
    T S Rai 2 Pty Ltd <Websta Super Fund A/C> 700,000 1.32%
    Gleneagle Securities (Aust) Pty Ltd 638,675 1.20%
    Tdf Properties Pty Ltd <The Tdf Property A/C> 599,339 1.13%
    Benlee Company Pty Ltd <The Benlee A/C> 594,398 1.12%
    Gleneagle Securities (Aust) Pty Ltd <House Prop A/C> 570,000 1.07%
    Satwant Kaur Rai 550,000 1.03%